CL2020000136A1 - Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih. - Google Patents

Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih.

Info

Publication number
CL2020000136A1
CL2020000136A1 CL2020000136A CL2020000136A CL2020000136A1 CL 2020000136 A1 CL2020000136 A1 CL 2020000136A1 CL 2020000136 A CL2020000136 A CL 2020000136A CL 2020000136 A CL2020000136 A CL 2020000136A CL 2020000136 A1 CL2020000136 A1 CL 2020000136A1
Authority
CL
Chile
Prior art keywords
cobicistat
hiv
emtricitabine
treatment
compositions containing
Prior art date
Application number
CL2020000136A
Other languages
English (en)
Spanish (es)
Inventor
Katia Boven
Smedt Goedele De
Regina Driesen
Dominiek Henrist
Greet Kauwenberghs
Sandeep Mathur
Scott Mccallister
Roel Mertens
Richard Nettles
Magda Opsomer
William Pryz
Vahid Zia
Original Assignee
Janssen Sciences Ireland Unlimited Co
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63168494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co, Gilead Sciences Inc filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CL2020000136A1 publication Critical patent/CL2020000136A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2020000136A 2017-07-20 2020-01-16 Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih. CL2020000136A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762534885P 2017-07-20 2017-07-20
US201762571384P 2017-10-12 2017-10-12
US201862623174P 2018-01-29 2018-01-29
US201862665339P 2018-05-01 2018-05-01

Publications (1)

Publication Number Publication Date
CL2020000136A1 true CL2020000136A1 (es) 2020-06-12

Family

ID=63168494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000136A CL2020000136A1 (es) 2017-07-20 2020-01-16 Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih.

Country Status (10)

Country Link
US (1) US10786518B2 (enExample)
EP (3) EP4696309A3 (enExample)
JP (2) JP2020528409A (enExample)
AU (1) AU2018304373B2 (enExample)
BR (1) BR112020000842A2 (enExample)
CA (1) CA3070713A1 (enExample)
CL (1) CL2020000136A1 (enExample)
MA (1) MA49635A (enExample)
MX (1) MX2020000694A (enExample)
WO (1) WO2019018676A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180963A1 (en) * 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920110A (en) 1952-12-11 1960-01-05 Ethyl Corp Preparation of meta dichloro- and dibromo-benzenes
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN103841962B (zh) 2011-07-07 2016-08-17 爱尔兰詹森科学公司 地瑞纳韦配制品
PL2729130T3 (pl) * 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Also Published As

Publication number Publication date
BR112020000842A2 (pt) 2020-07-21
MX2020000694A (es) 2020-07-29
EP4696309A2 (en) 2026-02-18
WO2019018676A1 (en) 2019-01-24
CA3070713A1 (en) 2019-01-24
US10786518B2 (en) 2020-09-29
EP4778527A2 (en) 2026-07-22
US20190022113A1 (en) 2019-01-24
JP2023123523A (ja) 2023-09-05
EP4696309A3 (en) 2026-04-22
MA49635A (fr) 2020-05-27
AU2018304373A1 (en) 2020-01-30
AU2018304373B2 (en) 2024-08-01
JP2020528409A (ja) 2020-09-24
EP3654951B1 (en) 2026-08-05
EP3654951A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CL2020000299A1 (es) Compuestos, composiciones y métodos.
SV2018005778A (es) Derivados aromaticos de sulfonamida
BR112018071585A2 (pt) formulações de um inibidor de lsd1
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
CL2016002971A1 (es) Combinación.
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
JOP20180026A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR106025A1 (es) Formas cristalinas de ácido siálico o una sal o solvato de este
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2020000694A (es) Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
MX2017013795A (es) Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina